Bin Yang received a Ph.D. degree in medicinal chemistry with honors from Academy of Military Medical Science, Beijing, China, in 1996. He served as an assistant investigator from 1996 to 1999 in the Beijing Institute of Pharmacology and Toxicology. After postdoctoral research at University of Illinois at Urbana-Champaign and Thomas Jefferson University, he came to Indiana University in 2004 as a research associate. He was later promoted to assistant scientist rank. In the period of 2008 to 2011 he was director of peptide chemistry at Marcadia Biotech, a Roche acquired biopharmaceutical company developing cutting-edge therapeutics for treatment of diabetes and obesity.
Dr. Yang's research background encompasses a diverse field of medicinal chemistry, peptide & protein, and bioconjugate chemistries. He was also well-versed in molecular and cellular biology. His current interests are focused on structure-activity relationships of medicinally important peptides & proteins. He is a co-inventor of several patents that pertain to discovery and optimization of drug candidates currently being advanced for the treatment of the metabolic syndrome.